NeuroMetrix (NASDAQ:NURO) Issues Quarterly Earnings Results

NeuroMetrix (NASDAQ:NURO) posted its quarterly earnings results on Tuesday. The medical device company reported ($0.75) earnings per share for the quarter, RTT News reports. The business had revenue of $0.59 million during the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. During the same period in the previous year, the company earned ($1.66) earnings per share.

NeuroMetrix Trading Up 1.7 %

NURO traded up $0.06 during midday trading on Wednesday, reaching $3.61. The company’s stock had a trading volume of 10,835 shares, compared to its average volume of 26,236. The firm has a market capitalization of $7.33 million, a price-to-earnings ratio of -0.65 and a beta of 2.29. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $4.73. The stock’s 50-day moving average is $4.04 and its 200-day moving average is $3.88.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of NeuroMetrix in a research note on Monday. They set a “sell” rating for the company.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.